STRO sutrobio.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
Sutro Biopharma, Inc. (STRO) is developing targeted immunotherapy and antibody-drug conjugates, mitigating risks through partnerships to treat various tumors. High demand for innovative cancer treatments is driving the expansion of its agreement network, while the price trajectory of the securities on GURU.Markets based on the EV/EBITDA metric is fixed at 0.00. Sutro Biopharma, Inc. (STRO) monetizes its technological platform, securing stable funding through long-term contracts with global industry leaders.
פילוחי נתונים אנליטיים מרוכזים עבור sutrobio.com (STRO)
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest, allowing for an assessment of the actual payback period of assets regardless of debt load. By analyzing the dynamic EV/EBITDA metric of the company, an investor can evaluate the stability of Sutro Biopharma, Inc. (STRO), where the risk of narrow specialization in ovarian cancer therapy is offset by the inflow of capital from global strategic partners.
